Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alkermes

Bellus Health Inc

Immunocore Holdings

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Has Geron (GERN) Outpaced Other Medical Stocks This Year?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET. A webcast of the pr

Geron to Present at the H.C. Wainwright Global Investment Conference

Investors are reacting positively to the company's Q1 update.

Why Geron Stock Is Soaring Today

Geron Corporation. (NASDAQ:GERN ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Aron Feingold - VP of Investor Relations and Corporate Communications Olivia Bloom - Executive VP of Finance and Chief Financial Officer and Treasurer John Scarlett - Chairman and Chief Executive Officer Aleksandra Rizo - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President-Corporate Strategy and Chief Commercial Officer Conference Call Participants Gil Blum - Needham & Company Stephen Willey - Stifel Justin Walsh - B.

Geron Corporation (GERN) CEO John Scarlett on Q1 2022 Results - Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the first quarter of 2022, including current and projected financial resources. “This quarter, we continued to build on the momentum from our clinical execution throughout 2021, with our first Phase 3 data readout expected in just eight months.

Geron Corporation Reports First Quarter 2022 Financial Results

Top line results or TLR from the IMerge phase 3 trial will be out by January 2023. This is a confirmatory trial that may lead to an NDA, if successful.

Geron: TLR Is 10 Months Away

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2022 financial results after the market closes on Monday, May 9, 2022 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent highlights at 4:30 p.m. ET the same day. A live webcast of the conference call and related presentation will be available

Geron to Announce First Quarter 2022 Financial Results on May 9, 2022

Rivian Automotive

Vaxart

These stocks are expected to grow their sales by 26,519% to 100,236% over the next five years.

3 of the Fastest-Growing Stocks on the Planet Through 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, plans to present a company overview at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET. A live webcast of the presentation will be available through the

Geron to Present at the 21st Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of common stock, together with accompanying warrants to purchase 35,714,286 shares of common stock. The combined offering price to the public of each share of common stock and accompanying warrant w

Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants

The late clinical-stage biopharmaceutical company is raising money through a stock offering.

Why Geron's Shares Rose 23.4% on Wednesday

Mullen Automotive

Romeo Power

Which penny stocks are you watching right now? The post Hot Penny Stocks That Investors Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks That Investors Are Watching Right Now

Adagio Therapeutics

Direct Digital Holdings

NanoVibronix

Sonoma Pharmaceuticals

Vyant Bio

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of its common stock, together with accompanying warrants to purchase 35,714,286 shares of its common stock. The combined offering price to the public of each share of common stock and accompanying w

Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of its common stock, pre-funded warrants to purchase shares of its common stock, together with accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering ar

Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

Tellurian

VEON

Unusual options activity places these penny stocks in the hot seat. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 To Watch Now With Unusual Options Activity

Geron Corporation's (GERN) CEO John Scarlett on Q4 2021 Results - Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones

Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Present at the H.C. Wainwright BioConnect Conference

Geron to Present at the H.C. Wainwright BioConnect Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Reports Presentations at American Society of Hematology Annual Meeting

Geron Reports Presentations at American Society of Hematology Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Announces Appointment of Chief Business Officer

Geron Announces Appointment of Chief Business Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, will present a company overview at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:40 p.m. ET. A live webcast of the presentation will be available through the Investor Re

News for Geron Stock (GERN)